$36.17
0.90% day before yesterday
Nasdaq, May 09, 10:00 pm CET
ISIN
US30161Q1040
Symbol
EXEL

Exelixis, Inc. Stock price

$36.17
+0.83 2.35% 1M
-0.02 0.06% 6M
+2.87 8.62% YTD
+14.41 66.22% 1Y
+16.83 87.02% 3Y
+8.75 31.91% 5Y
+32.77 963.82% 10Y
Nasdaq, Closing price Fri, May 09 2025
-0.33 0.90%
ISIN
US30161Q1040
Symbol
EXEL
Sector
Industry

Key metrics

Market capitalization $9.97b
Enterprise Value $9.07b
P/E (TTM) P/E ratio 20.41
EV/FCF (TTM) EV/FCF 13.51
EV/Sales (TTM) EV/Sales 4.18
P/S ratio (TTM) P/S ratio 4.60
P/B ratio (TTM) P/B ratio 4.54
Revenue growth (TTM) Revenue growth 18.49%
Revenue (TTM) Revenue $2.17b
EBIT (operating result TTM) EBIT $689.95m
Free Cash Flow (TTM) Free Cash Flow $671.54m
Cash position $1.11b
EPS (TTM) EPS $1.77
P/E forward 17.97
P/S forward 4.43
EV/Sales forward 4.03
Short interest 9.04%
Show more

Is Exelixis, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,793 stocks worldwide.

Exelixis, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a Exelixis, Inc. forecast:

11x Buy
52%
10x Hold
48%

Analyst Opinions

21 Analysts have issued a Exelixis, Inc. forecast:

Buy
52%
Hold
48%

Financial data from Exelixis, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
2,169 2,169
18% 18%
100%
- Direct Costs 76 76
5% 5%
4%
2,092 2,092
19% 19%
96%
- Selling and Administrative Expenses 463 463
8% 8%
21%
- Research and Development Expense 910 910
13% 13%
42%
719 719
241% 241%
33%
- Depreciation and Amortization 29 29
27% 27%
1%
EBIT (Operating Income) EBIT 690 690
304% 304%
32%
Net Profit 521 521
151% 151%
24%

In millions USD.

Don't miss a Thing! We will send you all news about Exelixis, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Exelixis, Inc. Stock News

Neutral
Business Wire
4 days ago
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in May: BofA Securities 2025 Health Care Conference: Exelixis is scheduled to present at 1:40 p.m. ET / 10:40 a.m. PT on Wednesday, May 14 in Las Vegas. RBC Capital Markets 2025 Global Healthcare Conference: Exelixis is ...
Neutral
Business Wire
12 days ago
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2025 financial results will be released on Tuesday, May 13, 2025 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet ...
Positive
Investors Business Daily
15 days ago
Stocks near buy points include Charles Schwab, German software leader SAP and MercadoLibre, the so-called Amazon of Latin America,
More Exelixis, Inc. News

Company Profile

Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in Alameda, CA.

Head office United States
CEO Michael Morrissey
Employees 1,147
Founded 1994
Website www.exelixis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today